natgillin/translations-raw huggingface dataset:
RB is independently selected at each occurrence from hydrogen; or C1-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in RB is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl; 
Rd je svaki neovisno odabran pri svakom pojavljivanju od vodika; ili C1-C6alkila, C2-C6alkenila ili c2-c6alkinila, od kojih je svaki neovisno po izboru supstituiran pri svakom pojavljivanju s jednim ili s više supstituenata odabranih od halogena, hidroksi, merkapto, amino, karboksi, nitro, okso, fosfonoksi, fosfono, tiokso, formila, cijano ili 3- do 6-eročlanog karbocikla ili heterocikla; ili 3- do 6-eročlanog karbocikla ili heterocikla; pri čemu svaki 3- do 6-eročlani karbocikl ili heterocikl u Rb je neovisno po izboru supstituiran pri svakom pojavljivanju s jednim ili s više supstituenata odabranih od halogena, hidroksi, merkapto, amino, karboksi, nitro, okso, fosfonoksi, fosfono, tiokso, formila, cijano, C1-C6alkila, C2-C6alkenila, C2-C6alkinila, -C6haloalkila, C2-C6haloalkenila ili C2-C6haloalkinila;
each R4 is, independently, H or C1-4 alkyl; or two R4 groups, together with the carbon atom to which they are attached, form a 3-, 4-, 5-, or 6-membered cycloalkyl ring; 
svaka R4 je,nezavisno, H ili C1-4 alkil; ili dvije R4 grupe, zajedno sa atomom ugljika na koji su vezane, formiraju 3-, 4-, 5-, ili 6-člani prsten cikloalkila;
each R4b is, independently, H or C1-4 alkyl; or two R4b groups, together with the carbon atom to which they are attached, form a 3-, 4-, 5-, or 6-membered cycloalkyl ring; 
svaka R4b je, nezavisno, H ili C1-4 alkil; ili dvije R4b grupe, zajedno sa atomom ugljika na koji su vezane, formiraju 3-, 4-, 5-, ili 6- člani prsten cikloalkila;
two R1 groups form a 2-carbon bridge. 
dvije R1 grupe formiraju dvočlani ugljikov most.
A is phenyl, a naphthyl ring, monocyclic C3-10 cycloalkyl, bicyclic C3-10 cycloalkyl, monocyclic C2-10 heterocycloalkyl, bicyclic C2-10 heterocycloalkyl, monocyclic C1-10heteroaryl, or bicyclic C1-10heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R5 groups; or 
A je fenil, prsten naftila, monociklički C3-10 cikloalkil, biciklički C3-10 cikloalkil, monociklički C2-10 heterocikloalkil, biciklički C2-10 heterocikloalkil, monociklički C1-10 heteroaril, ili biciklički C1-10 heteroaril; od kojih je svaki opcijski supstituiran sa 1, 2, 3, 4, ili 5 nezavisno izabranih R5 grupa; ili
A is methyl, ethyl, isopropyl, phenyl, a naphthalene ring, a pyridine ring, a pyrimidine ring, a thiophene ring, a pyrazine ring, an oxazole ring, an isoxazole ring, an imidazole ring, a thiazole ring, a furan ring, a pyrazole ring, a quinoline ring, a benzothiophene ring, a benzothiazole ring, a benzoimidazole ring, a benzofuran ring, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, an indene ring, a tetrahydronaphthalene ring, dihydro-1,4-benzodioxoxine ring, or a piperidine ring; each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R5 groups, as permitted by valency; or 
A je metil, etil, izopropil, fenil, prsten naftila, prsten piridina, prsten pirimidina, prsten tiofena, prsten pirazina, prsten oksazola, prsten izoksazola, prsten imidazola, prsten tazola, prsten furana, prsten pirazola, prsten hinolina, prsten benzotiofena, prsten benzotiazola, prsten benzoimidazola, prsten benzofurana, ciklopropil, ciklopentil, cikloheksil, cikloheptil, prsten indena, prsten tetrahidronaftalena, prsten dihidro-1,4-benzodioksolksin, ili prsten piperidina; od kojih je svaki opcijski supstituiran sa 1, 2, 3, 4, ili 5 nezavisno izabranih R5 grupa, kao što je dopušteno valencijom; ili
or any Rc1 and Rd1 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group, optionally substituted with 1, 2, 3 or 4 substituents independently selected from halo; or 
ili bilo koja Rc1 i Rd1 zajedno sa atomom N na koji su vezane, formiraju 4-, 5-, 6-, ili 7-članu heterocikloalkil grupu, opcijski supstituirano sa 1, 2, 3 ili 4 supstituenata nezavisno izabranih od halo; ili
each R1 is, independently, C1-4 alkyl; or two R1 groups form a 2-carbon bridge. 
svaka R1 je, nezavisno, C1-4 alkil; ili dvije R1 grupe formiraju dvočlani ugljikov most.
each R1 is, independently, methyl; or two R1 groups form a 2-carbon bridge. 
svaka R1 je, nezavisno, metil; ili dvije R1 grupe formiraju dvočlani ugljikov most.
each R1 is, independently, C1-4 alkyl, hydroxyl, C1-4 alkoxy, or fluoro; two R1 groups together form a 2- or 3-carbon bridge or a bridge of formula -CH2-O-CH2-; 
svaka R1 je, nezavisno, C1-4 alkil, hidroksil, C1-4 alkoksi, ili fluoro; dvije R1 grupe zajedno formiraju dvočlani ili tročlani ugljikov most ili most od formule -CH2-O-CH2-;
A is C1-6 alkyl, phenyl, a naphthyl ring, monocyclic C3-10 cycloalkyl, bicyclic C3-10 cycloalkyl, monocyclic C2-10 heterocycloalkyl, bicyclic C2-10 heterocycloalkyl, monocyclic C1-10 heteroaryl, or bicyclic C1-10 heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R5 groups; 
A je C1-6 alkil, fenil, prsten naftila, monociklički C3-10 cikloalkil, biciklički C3-10 cikloalkil, monociklički C2-10 heterocikloalkil, biciklički C2-10 heterocikloalkil, monociklički C1-10 heteroaril, ili biciklički C1-10 heteroaril; od kojih je svaki opcijski supstituiran sa 1, 2, 3, 4, ili 5 nezavisno izabranih R5 grupa;
the compound is selected from: 
Spoj je izabran od:
the compound is selected from: 
spoj je izabrano od:
The salt according to claim 15, which is characterized by a melting point of about 178 °C. 
Sol prema patentnom zahtjevu 15, naznačena time da je karakterizirana točkom taljenja od oko 178 °C.
an X-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at about 23.3; or 
obrazac rendgenske difrakcije praha koji sadrži karakteristični pik izražen u stupnjevima 2Ɵ na oko 23.3; ili
an X-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at about 6.9, 10.4, 21.0, and 23.3; or 
obrazac rendgenske difrakcije praha koji sadrži karakteristični pik izražen u stupnjevima 2Ɵ na oko 6.9,, 21.0, i 23.3; ili
said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder; or 
navedena autoimuna bolest je kožni poremećaj, multipla skleroza, reumatoidni artritis, psorijačni artritis, juvenilni artritis, dijabetes tipa I, lupus, inflamatorna bolest crijeva, Kronova bolest, mijastenija gravis, imunoglobulinska nefropatija, miokarditis, ili autoimuni poremećaj štitnjače, ili
said autoimmune disease is rheumatoid arthritis; or 
navedena autoimuna bolest je reumatoidni artritis; ili
said autoimmune disease is a skin disorder; or 
navedena autoimuna bolest je kožni poremećaj; ili
said autoimmune disease is a skin disorder which is atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization; or 
navedena autoimuna bolest je kožni poremećaj koji je atopijski dermatitis, psorijaza, osjetljivost kože, iritacija kože, osip na koži, kontaktni dermatitis ili alergijska kontaktna osjetljivost; ili
said cancer is a solid tumor; or 
navedeni rak je solidni tumor; ili
said cancer is lymphoma, leukemia, or multiple myeloma; or 
navedeni rak je limfom, leukemija, ili multipli mijelom; ili
said myeloproliferative disorder is myelofibrosis; or 
navedeni mijeloproliferativni poremećaj je mijelofibroza; ili
said myeloproliferative disorder is primary myelofibrosis (PMF); or 
navedeni mijeloproliferativni poremećaj je primarna mijelofibroza (PMF); ili
comprising any one of the nucleotide sequences (a), (b) and (c) below: 
obuhvaća bilo koju od dolje navedenih nukleotidnih sekvenci, (b) i (c):
having a base length of not more than 73. 
obuhvaća baznu duljinu koja nije veća od 73 baza.
An anti-pain agent comprising the aptamer according to any one of claims 1 to 10 or the complex of claim 11. 
Sredstvo protiv bolova, naznačeno time, da obuhvaća aptamer prema bilo kojem od zahtjeva 1 do 10, ili kompleks prema zahtjevu 11.
A crystalline form according to claim 1, wherein the x-ray powder diffraction spectrum is substantially the same as the x-ray powder diffraction spectrum shown in Figure 7. 
Kristalni oblik prema zahtjevu 1, naznačen time, da je njegov spektar difrakcije praha X-zraka temeljno isti kao spektar difrakcije praha X-zraka prikazan na Slici 7.
A crystalline form according to claim 1, wherein the differential scanning calorimetry thermogram is substantially the same as that shown in Figure 8. 
Kristalni oblik prema zahtjevu 1, naznačen time, da je njegov kalorimetrijski termogram diferencijalnog skeniranja temeljno isti kao i onaj prikazan na Slici 8.
A pharmaceutical composition comprising the crystalline form according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav, naznačen time, da obuhvaća kristalni oblik prema bilo kojem od zahtjeva 1 do 4 te farmaceutski prikladan nosač ili razrjeđivač.
A pharmaceutical composition according to claim 5 in combination with one or more additional active ingredients. 
Farmaceutski sastav prema zahtjevu 5, naznačen time, da je u kombinaciji s jednim ili više dodatnih djelatnih sastojaka.
A pharmaceutical composition according to claim 5 or 6, which is in inhalable form. 
Farmaceutski sastav prema zahtjevu 5 ili 6, naznačen time, da postoji u inhalacijskom obliku.
An inhalation device that contains and is adapted to deliver a crystalline form according to any one of claims 1 to 4 by pulmonary administration. 
Uređaj za inhalaciju, naznačen time, da sadrži kristalni oblik prema bilo kojem od zahtjeva 1 do 4 i prilagođen je za dostavu toga sadržaja putem pulmonalne primjene.
is selected from the group consisting of hydrogen, halogen, cyano, and (C1-C6) alkoxy; 
je odabran iz skupine koju čine: vodik, halogen cijano i (C1-C6)alkoksi;
is selected from the group consisting of carboxy, tetrazole, oxadiazolone, thiadiazolone, methylsulfonylcarbamoyl, and N-hydroxycarbamoyl. 
je odabran iz skupine koju čine: karboksi, tetrazol, oksadiazolon, tiadiazolon, metilsulfonilkarbamoil i N-hidroksikarbamoil.
is selected from the group consisting of hydrogen, fluoro, chloro, methoxy, and cyano; and R3 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, CF3, methoxy, cyano, and N, N-dimethylamino. 
je odabran iz skupine koju čine: vodik, fluoro, kloro, metoksi i cijano; i R3 je odabran iz skupine koju čine: vodik, fluoro, kloro, metil, CF3, metoksi, cijano i N,N-dimetilamino.
The compound or salt of Claim 1 wherein R1 is selected from the group consisting of hydrogen, CF3, CF2H, methyl, and 4-carboxybenzyl; 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: vodik, CF3, CF2H, metil i 4-karboksibenzil;
is selected from the group consisting of hydrogen and fluoro; 
je odabran iz skupine koju čine: vodik i fluoro;
is selected from the group consisting of hydrogen, fluoro, chloro, and methyl; 
je odabran iz skupine koju čine: vodik, fluoro, kloro i metil;
A compound or salt as defined in any of claims 1 to 8 or a pharmaceutical composition as defined in claim 9 for use in a method of treatment of a disease or condition. 
Spoj ili sol prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski sastav prema zahtjevu 9, naznačen/a time, da se upotrebljava u postupku liječenja bolesti ili stanja.
A compound or salt as defined in any of claims 1 to 8 or a pharmaceutical composition as defined in claim 9 for use in a method of treatment of asthma. 
Spoj ili sol prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski sastav prema zahtjevu 9, naznačen/a time, da se upotrebljava u postupku liječenja astme.
A compound or salt as defined in any of claims 1 to 8 or a pharmaceutical composition as defined in claim 9 for use in a method of treatment of inflammatory bowel disease or cystic fibrosis. 
Spoj ili sol prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski sastav prema zahtjevu 9, naznačen/a time, da se upotrebljava u postupku liječenja upalne bolesti crijeva ili cistične fibroze.
A salt of the compound of formula (I) according to claim 1 wherein the salt is an acid addition salt. 
Sol spoja formule (I) prema patentnom zahtjevu 1 pri čemu je sol adiciona sol kiseline.
A salt of the compound of formula (I) according to claim 1 wherein the salt is a trihydrochloride dihydrate salt. 
Sol spoja formule (I) prema patentnom zahtjevu 1 pri čemu je sol trihidroklorid dihidrat sol.
A trihydrochloride dihydrate salt of the compound of formula (I) according to claim 6 having: 
Trihidroklorid dihidrat sol spoja formule (I) prema patentnom zahtjevu 6 imajući:
The pharmaceutical composition of claim 9, wherein said composition is in the form of a tablet or capsule. 
Farmaceutski pripravak patentnog zahtjeva 8, pri čemu je spomenuti pripravak u obliku tablete ili kapsule.
A compound or salt of any of claims 1-7 for use in treating an ALK- or FAK-mediated condition or disorder selected from anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), neuroblastoma, glioblastoma, prostate cancer, squamous cell carcinoma (SCC), and breast cancer. 
Spoj ili sol bilo kojeg od patentnih zahtjeva od 1 do 7 za upotrebu u liječenju ALK- ili FAK- posredovanog stanja ili poremećaja izabrano od anaplastičkog limfoma velikih ćelija (ALCL), nemalog ćelijskog raka pluća (NSCLC), neuroblastoma, glioblastoma, raka prostate, raka skvamoznih ćelija (SCC), i raka dojke.
The compound for use of claim 10, wherein the ALK- or FAK-mediated condition or disorder is selected from: 
Spoj za upotrebu iz patentnog zahtjeva 10, pri čemu je ALK- ili FAK- posredovano stanje ili poremećaj izabrano od:
The compound for use of claim 10, wherein the ALK- or FAK-mediated condition or disorder is selected from androgen-independent prostate cancers, breast cancers, and HNSCCs. 
Spoj za upotrebu iz patentnog zahtjeva 10, pri čemu ALK- ili FAK- posredovano stanje ili poremećaj je izabrano od androgeno nezavisnih karcinoma prostate, karcinoma dojki, i HNSCCs.
The compound for use of claim 10, wherein the ALK- or FAK-mediated condition or disorder is an ALK-mediated condition or disorder. 
Spoj za upotrebu iz patentnog zahtjeva 10, pri čemu ALK- ili FAK- posredovano stanje ili poremećaj je ALK- posredovano stanje ili poremećaj.
The compound for use of claim 10, wherein the ALK- or FAK-mediated condition or disorder is a FAK-mediated condition or disorder. 
Spoj za upotrebu iz patentnog zahtjeva 10, pri čemu ALK- ili FAK- posredovano stanje ili poremećaj je FAK-posredovano stanje ili poremećaj.
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6 alkyl, halo-C1-6 alkyl, halogen and CF3; 
Q je izabran iz grupe koja se sastoji od fenil, piridil, tiazolil, tiofenil, pirimidil, svaka izborno supstituirana sa jednom ili dvije grupe nezavisno izabrane iz grupe koja se sastoji od C1-6alkil, halo-C1-6 alkil, halogen i CF3;
Y is selected from N or CH; 
Y je izabran od N ili CH;
is selected from the group consisting of hydrogen, C1-3 alkyl, C3-6 cylcoalkyl, C4-5 alkylcycloalkyl, wherein C1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy or C1-6 alkoxy; 
je izabran iz grupe koja se sastoji od vodika, C1-3 alkil, C3-6 cikloalkil, C4-5 alkilcikloalkil, gdje je C1-3 alkil izborno supstituiran sa 1 do 3 supstituenta nezavisno izabrana od halogena, hidroksi ili C1-6alkoksi;
The compound for use according to claim 7 wherein the disease is selected from non-malignant hyperproliferative disorders and malignant hyperproliferative disorders, specifically of hepatocellular carcinoma, colon adenoma and polyposis, colon adenocarcinoma, breast cancer, pancreas adenocarcinoma, Barrett's esophagus or other forms of neoplastic diseases of the gastrointestinal tract and the liver. 
Spoj za uporabu prema patentnom zahtjevu 10 naznačen time što je bolest izabrana od nemalignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, posebnoo hepatostaničnog karcinoma, adenoma debelog crijeva i polipoza, adenokarcinoma debelog crijeva, kancera dojke, adenokarcinoma pankreasa, Barett-ovog jednjaka ili drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
The use according to claim 11 wherein the disease is selected from non-malignant hyperproliferative disorders and malignant hyperproliferative disorders, specifically of hepatocellular carcinoma, colon adenoma and polyposis, colon adenocarcinoma, breast cancer, pancreas adenocarcinoma, Barrett's esophagus or other forms of neoplastic diseases of the gastrointestinal tract and the liver. 
Uporaba prema patentnom zahtjevu 14 naznačena time što je bolest izabrana od nemalignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, posebno hepatostaničnog karcinoma, adenoma debelog crijeva i polipoza, adenokarcinoma debelog crijeva, kancera dojke, adenokarcinoma pankreasa, Barett-ovog jednjaka ili drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
An IgG antibody that binds human receptor tyrosine kinase FLT3, said antibody comprising a heavy chain and a light chain and an amino acid substitution in the constant region relative to a parent anti-FLT3 antibody, wherein said amino acid substitution comprises the amino acid substitutions S239D and I332E, wherein the positional numbering is according to the EU index. 
IgG protutijelo koje se veže na ljudsku receptorsku tirozinsku kinazu FLT3, naznačeno time što navedeno protutijelo sadrži teški lanac i laki lanac, te aminokiselinu zamjenu u konstantnom području u odnosu na osnovno protutijelo protiv FLT3, gdje se navedena aminokiselina zamjena sastoji u aminokiselinskim zamjenama S239D i I332E, gdje je pozicijsko numeriranje izvršeno u skladu s EU indeksom.
The antibody of claim 1, wherein the antibody is a chimeric antibody and comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:27 and a light chain having the amino acid sequence set forth in SEQ ID NO:23. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je protutijelo kimerno protutijelo i sadrži teški lanac čiji je aminokiselinski slijed iznijet u SEQ ID NO:27 i laki lanac čiji je aminokiselinski slijed iznijet u SEQ ID NO:23.
The antibody of claim 1, wherein the antibody is a chimeric antibody and comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:43 and/or a light chain having the amino acid sequence set forth in SEQ ID NO:39. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je protutijelo kimerno protutijelo i sadrži teški lanac čiji je aminokiselinski slijed iznijet u SEQ ID NO:43 i/ili laki lanac čiji je aminokiselinski slijed iznijet u SEQ ID NO:39.
A nucleic acid molecule encoding a heavy and light chain of the antibody of any one of claims 1-8. 
Molekula nukleinske kiseline, naznačena time što kodira teški i laki lanac protutijela u skladu s bilo kojim od patentnih zahtjeva 1-8.
The antibody for use according to any one of claims 10-12, wherein said antibody is administered in combination with at least one agent selected from the group consisting of a cytotoxic agent, a chemotherapeutic agent, a cytokine, a growth inhibitory agent, an anti-hormonal agent, a kinase inhibitor, an anti-angiogenic agent, a cardioprotectant, an immunostimulatory agent, an immunosuppressive agent, an angiogenesis inhibitor, a protein tyrosine kinase inhibitor, and second antibody. 
Protutijelo namijenjeno upotrebi u skladu s bilo kojm od patentnih zahtjeva 10-12, naznačeno time što se navedeno protutijelo primjenjuje u kombinaciji s najmanje jednim sredstvom koje se bira iz skupine koju čine citotoksično sredstvo, kemoterapijsko sredstvo, citokin, sredstvo za inhibiranje rasta, antihormonsko sredstvo, inhibitor kinaza, antiangiogensko sredstvo, kardioprotektiv, imunostimulacijsko sredstvo, imunosupresivno sredstvo, inhibitor angiogeneza, inhibitor proteinskih tirozinskih kinaza, i drugo protutijelo.
A pharmaceutical composition according to claim 5 in unit dosage form. 
Farmaceutski sastav prema zahtjevu 5. naznačen time, da se nalazi u obliku dozne jedinice.
A pharmaceutical composition according to claim 7 wherein the unit dosage form contains 5 mg to 100 mg of a compound of formula (Ia) or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav prema zahtjevu 7, naznačen time, da oblik dozne jedinice sadrži od 5 mg do 100 mg spoja formule (Ia) ili njegove farmaceutski prihvatljive soli.
A compound, pharmaceutical composition, or combination for use according to claim 13 or the use of a compound, a pharmaceutical composition, or a combination according to claim 14, wherein said susceptible neoplasm is selected from breast cancer, cholangiocarcinoma, colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer and thyroid cancer. 
Spoj, farmaceutski sastav ili kombinacija za uporabu prema zahtjevu 13, ili uporaba spoja, farmaceutskog sastava ili kombinacije prema zahtjevu 14, naznačen/a time, da je navedena osjetljiva neoplazma odabrana od raka dojke, kolangiokarcinoma, kolorektalnog raka, melanoma, raka ne-malih stanica pluća, raka jajnika i tiroidnog raka.
A compound, pharmaceutical composition, or combination for use according to claim 13 or the use of a compound, a pharmaceutical composition, or a combination according to claim 14, wherein said susceptible neoplasm is a melanoma. 
Spoj, farmaceutski sastav ili kombinacija za uporabu prema zahtjevu 13, ili uporaba spoja, farmaceutskog sastava ili kombinacije prema zahtjevu 14, naznačen/a time, da navedena osjetljiva neoplazma je melanom.
A compound, pharmaceutical composition, or combination for use or the use of a compound, a pharmaceutical composition, or a combination according to claim 16, wherein said melanoma is a metastatic melanoma. 
Spoj, farmaceutski sastav ili kombinacija za uporabu, ili uporaba spoja, farmaceutskog sastava ili kombinacije prema zahtjevu 16, naznačen/a time, da navedeni melanom je melanom koji metastazira.
A compound, pharmaceutical composition, or combination for use according to claim 13 or the use of a compound, a pharmaceutical composition, or a combination according to claim 14, wherein the susceptible neoplasm is a neoplasm which exhibits a mutation in BRaf. 
Spoj, farmaceutski sastav ili kombinacija za uporabu prema zahtjevu 13, ili uporaba spoja, farmaceutskog sastava ili kombinacije prema zahtjevu 14, naznačen/a time, da navedena osjetljiva neoplazma je neoplazma koja pokazuje mutaciju u BRaf.
A compound, pharmaceutical composition, or combination for use or the use of a compound, a pharmaceutical composition, or a combination according to claim 18, wherein the mutation results in the BRaf having a V600E amino acid substitution. 
Spoj, farmaceutski sastav ili kombinacija za uporabu, ili uporaba spoja, farmaceutskog sastava ili kombinacije prema zahtjevu 18, naznačen/a time, da mutacija koja rezultira u BRaf, ima aminokiselinsku supstituciju V600E.
A composition comprising a folate for use in a method for treating cerebrospinal folate deficiency in an individual with hypothyroidism, said method comprising: 
Pripravak koji sadrži folat za uporabu u postupku liječenja cerebrospinalne folatne deficijencije u pojedinca s hipotiroidizmom, taj postupak obuhvaća: